Celldex Therapeutics is a biopharmaceutical company based in Fall River, MA, specializing in the development of transformative antibody therapeutics. Their lead program, barzolvolimab, is a humanized monoclonal antibody inhibitor of KIT, targeting mast cells and offering potential treatment options for severe inflammatory, allergic, and autoimmune diseases.
Driven by their extensive experience in antibody-based immunotherapies, Celldex utilizes proprietary antibody programs and technologies to optimize the discovery and development of innovative scientific programs. Their focus lies at the intersection of mast cell biology and the advancement of antibody therapeutics, aiming to improve the lives of patients affected by various diseases.
Generated from the website